GeneCode and Argobio Partners

We are very honored to share the news of the GeneCode and Argobio Partners on Parkinson’s Disease in Argobio’s First Announced Research Agreement. Read more: https://www.argobiostudio.com/pdf/2021-12-16-PR_Genecode_ArgoBio_EN_VF.pdf

Read More

Freedom to Operate

GeneCode ordered a Freedom to Operate search on a group of chemical compounds from international patent and trademark attorneys. (Project period: 07.04.2021-08.08.2021). According to the final analysis, the patents were discovered alive and are not relevant concerning GeneCode’s freedom to operate. The project was partly financed by the European Regional Development Fund with 1760 euros.

Read More

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6- Hydroxydopamine Model of Parkinson’s Disease

Current Parkinson’s Disease treatments only relieve symptoms without halting the progression of the disease, and their use is complicated by severe adverse effects emerging as the disease progresses. Therefore, there is an urgent need for new therapies for PD management. We developed a small molecule compound, BT13, targeting receptor tyrosine kinase RET. Research article “GDNF…

Read More

Digital RESI Europe

Digital RESI Europe. GeneCode participated in the Virtual Partnering Conferences (23-25 March 2020). The goal of the partnering event was to match the fundraising CEOs and the scientist-entrepreneurs with investors and strategic partners that are a fit for their stage of development and product set. https://resiconference.com/

Read More

The new molecule shows promise for Parkinson’s treatment

The new molecule shows promise for Parkinson’s treatment. Recent research in mouse models suggests that a new molecule might be able to tap into key neurochemical mechanisms and help treat Parkinson’s disease. https://www.medicalnewstoday.com/articles/new-molecule-shows-promise-for-parkinsons-treatment

Read More

The summary of our findings – Parkinson’s UK

The summary of our findings written in layman’s terms can be found in the press release from Parkinson’s UK. A promising molecule, called BT13, has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do. https://www.parkinsons.org.uk/news/bt13-molecule-offers-hope-halting-parkinsons

Read More

The effects of a small molecule GDNF mimetic

Our first paper describing the effects of a small molecule GDNF mimetic, a compound called BT13, in a cell-based model of Parkinson’s and in vivo was published last week in the Journal of Movement Disorders! https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.27943

Read More

Tech Tour 2019 Nordic Venture Forum

GeneCode was selected to present PD development at the 17th edition of the Tech Tour 2019 Nordic Venture Forum in Copenhagen, 30th- 31st October. The competition was very strong, with over 140+ applications and 500 individual company assessments. https://techtour.com/events/2019/10/event-nordic-venture-forum-2019.html?pageId=3065876

Read More

UTILE Brokerage, Partnering and Networking Event

GeneCode participated in the UTILE Brokerage, Partnering and Networking Event in Trieste on the 16-18 October. The workshop offered an exciting opportunity to meet potential investors and partners, show achievements, network, engage, and enhance business prospects. https://techtour.com/events/2019/10/event-utile-brokerage-investment-and-partnering-event.html

Read More